[Clinical effects of oxybutynin hydrochloride (Pollakis)--especially in the treatment of pollakisuria, urgency and urinary incontinence].
The effects and the safety of oxybutynin hydrochloride were investigated in 52 patients, 17 male and 35 female, with the chief complaints of pollakisuria, urgency and urinary incontinence. Clinical responses to the drug were assessed mainly by the subjective symptoms of the patients. The diagnoses of these patients were neurogenic bladder in 17, unstable bladder in 16 and others in 19 patients. The average administration period was 66.8 days. The rate of global improvement (excellent and good) was 55% in the 2 mg dose given 3 times daily group, 68.2% in the 3 mg dose given 3 times daily group. Side effects, such as dry mouth, were observed in 2 of the 52 patients (3.8%), but no serious side effects were observed. The rate of global utility (remarkable and moderate) was 67.3%. These data indicate that oxybutynin hydrochloride seems to be useful and safe for the treatment of pollakisuria, urgency and urinary incontinence.
Yamauchi
K
K
Department of Urology, Kobayashi Hospital.
Ohashi
K
K
Osanai
H
H
Inagaki
N
N
Yamaguchi
S
S
Hashimoto
H
H
Yachiku
S
S
D000284:Administration, Oral; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D006801:Humans; D008333:Mandelic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D011141:Polyuria / Q000188:drug therapy; D001750:Urinary Bladder, Neurogenic / Q000150:complications; D014549:Urinary Incontinence / Q000188:drug therapy*; D014555:Urination Disorders / Q000188:drug therapy*
D008333:Mandelic Acids; C005419:oxybutynin